Quell Therapeutics
A clinical stage company transforming lives in immune mediated disease
Overview
Quell Therapeutics is a spinout from UCL, King’s College London and Hannover Medical School. This pioneering company uses cell engineering technology to treat a range of autoimmune diseases. AlbionVC via its university fund was the sole co-investor in the company’s Series A and Series A expansion in 2019. Quell has since raised a $156m Series B and struck a $2bn deal with Astra Zeneca. We continue to be highly impressed with the team’s commitment to improving life for those battling severe immune and inflammatory diseases.
“The partnership with AstraZeneca is another fantastic achievement by the Quell team and well done to all involved. AstraZeneca is a world-leading partner and this collaboration is a major step forward in the engineered Treg field. We are now on the cusp of entering the clinic and look forward with excitement to proving the transformative potential of Quell’s platform.”
Tanel Ozdemir, Investment Manager